Strides Pharma zooms with JV getting USFDA’s approval for Albendazole Tablets

11 Dec 2018 Evaluate

Strides Pharma Science is currently trading at Rs. 451.45, up by 20.70 points or 4.81% from its previous closing of Rs. 430.75 on the BSE.

The scrip opened at Rs. 422.50 and has touched a high and low of Rs. 452.25 and Rs. 417.00 respectively. So far 58675 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 875.72 on 27-Dec-2017 and a 52 week low of Rs. 334.10 on 08-Jun-2018.

Last one week high and low of the scrip stood at Rs. 470.40 and Rs. 417.00 respectively. The current market cap of the company is Rs. 3982.69 crore.

The promoters holding in the company stood at 30.79%, while Institutions and Non-Institutions held 47.54% and 21.68% respectively.

Strides Pharma Science’s Joint Venture (JV) -- Strides Vivimed Pte., Singapore has received approval for Albendazole Tablets USP 200 mg from the United States Food & Drug Administration (USFDA). This is the second generic approval by US FDA for Albendazole Tablets.

Albendazole Tablets is a generic version of Albenza Tablets of Amneal Pharmaceuticals, Inc. According to IQVIA MAT data, the US market for Albendazole Tablets USP 200 mg is approximately $100 million.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

878.65 -7.00 (-0.79%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×